Alcon Receives Positive NICE Recommendation for Jetrea
October 22, 2013 at 19:07 PM EDT
Alcon, the global leader in eye care, and second largest division of Novartis (NYSE: NVS ), is pleased that the National Institute for Health and Care Excellence (NICE) has recommended Jetrea® (ocriplasmin) as a clinically and cost-effective treatment option for eligible patients suffering from vitreomacular traction including when associated
